A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.
BACKGROUND
Iluvien (®) is a novel, nonbiodegradable, sustained-release drug delivery system (0.2 mg / d fluocinolone acetonide [FAC]) is indicated in Europe for the treatment of visual impairment associated with chronic diabetic macular edema (DME), considered to be less responsive to available therapies.
OBJECTIVE
To evaluate the safety and efficacy of FAC 190-mg implant in patients with chronic refractory DME other medical treatment options in clinical settings.
METHOD
Retrospective registry data was collected using a standard case report form (CRF). Prior to injection of intravitreal implant FAC, all patients were treated either with an antagonist of vascular endothelial growth factor (VEGF) and / or steroid (triamcinolone, dexamethasone implant). Patients were excluded from receiving FAC if they had a known history of an increase in intraocular pressure (IOP) after corticosteroid therapy, glaucoma, ocular hypertension, or contraindicated cited in the summary of product characteristics. Best-corrected visual acuity (BCVA) is the primary parameter studies. Central thickness of the fovea (CFT) and IOP was measured simultaneously. This parameter is recorded before and after injection of 190-mg implant FAC (between 1 week and 9 months). Injections carried out between May 2013 and March 2014.
RESULTS
Fifteen eyes of ten patients treated. Thirteen eyes (nine patients) were pseudophakic and seven eyes (five patients) vitrectomized before receiving treatment. BCVA improved in eleven eyes (73.3%), remained unchanged in two eyes (13.3%), and slightly decreased in the two eyes (13.3%) at the final follow-up visit to the elementary level. IOP increased in two patients and are controlled using a fixed-combination of IOP-lowering eyedrops or sectoral cyclocryotherapy (n = 1).
CONCLUSION
FAC 190-mg implant is efficacious and demonstrated favorable benefit-to-profile risk in a population of patients with chronic DME series of cases refractory to other therapy. Long-term Efficacy and safety in real-life settings is still being assessed at this center. FAC may offer important treatment option for patients with chronic refractory DME other treatment options.

nanobeads magnetic decorated by thermo-responsive PNIPAM shell as a medical platform for the efficient delivery of doxorubicin to the tumor cells.
medical nanoplatforms based cluster superparamagnetic nanoparticles decorated with thermo-responsive PNIPAM shell has been synthesized and used as drug carriers for doxorubicin (DOXO), a common chemotherapeutic agent. The nanosystem here developed has an overall diameter below 200 nm and exploit temperature responsive behavior of PNIPAM shell polymers for controlled loading and release DOXO.
This system has been tested in vitro on tumor cells and it clearly demonstrates the effectiveness of the drug and polymer encapsulation time-dependent cell death caused by the release of doxorubicin. Mobile comparative studies of DOXO loaded nanoplatform the presence or absence of an external magnet (0.3 T) indicate a synergistic effect of accumulation and increased toxicity of the system, when magnetically guided, so that the enhanced efficacy of the system.
Alpha-bungarotoxin CF488a |
|||
9-00005 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin, CF568 |
|||
9-00006 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-bungarotoxin, CF568 |
|||
9-00006 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin, CF594 |
|||
9-00007 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-bungarotoxin CF594 |
|||
9-00007 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin, CF633 |
|||
9-00009 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-bungarotoxin, CF633 |
|||
9-00009 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin |
|||
00010-1 | Biotium | 1MG | EUR 201.6 |
Description: Minimum order quantity: 1 unit of 1MG |
Fluorescein-Alpha-bungarotoxin |
|||
00011 | Biotium | 500uG | EUR 440.4 |
Description: Minimum order quantity: 1 unit of 500uG |
Tetramethylrhodamine-Alpha-bungarotoxin |
|||
00012 | Biotium | 500uG | EUR 459.6 |
Description: Minimum order quantity: 1 unit of 500uG |
Fluorescein-alpha-bungarotoxin: (10x50ug) |
|||
00013 | Biotium | 10ST | EUR 500.4 |
Description: Minimum order quantity: 1 unit of 10ST |
Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug) |
|||
00014 | Biotium | 10ST | EUR 559.2 |
Description: Minimum order quantity: 1 unit of 10ST |
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug) |
|||
00015 | Biotium | 500uG | EUR 559.2 |
Description: Minimum order quantity: 1 unit of 500uG |
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug) |
|||
00016 | Biotium | 10ST | EUR 627.6 |
Description: Minimum order quantity: 1 unit of 10ST |
Biotin-xx-a-bungarotoxin |
|||
00017 | Biotium | 500uG | EUR 519.6 |
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-Bungarotoxin, CF555 conjugate |
|||
9-00018 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-Bungarotoxin, CF555 conjugate |
|||
9-00018 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100ug |
Biotin-cAMP, diisopropylethylammonium salt: |
|||
00020 | Biotium | 1MG | EUR 376.8 |
Description: Minimum order quantity: 1 unit of 1MG |
Biotin-cAMP, diisopropylethylammonium salt: (20x50ug) |
|||
00020-1 | Biotium | 20ST | EUR 501.6 |
Description: Minimum order quantity: 1 unit of 20ST |
Biotin-cGMP, diisopropylethylammonium salt: |
|||
00021 | Biotium | 1MG | EUR 412.8 |
Description: Minimum order quantity: 1 unit of 1MG |
Biotin-cGMP, diisopropylethylammonium salt: (20x50ug) |
|||
00021-1 | Biotium | 20ST | EUR 537.6 |
Description: Minimum order quantity: 1 unit of 20ST |
Cyanine 644-cAMP: |
|||
00022 | Biotium | 1MG | EUR 589.2 |
Description: Minimum order quantity: 1 unit of 1MG |
Cyanine 644-cAMP: (20x50ug) |
|||
00022-1 | Biotium | 20ST | EUR 750 |
Description: Minimum order quantity: 1 unit of 20ST |
Fluorescein Methotrexate, triammonium salt: |
|||
00023 | Biotium | 1MG | EUR 337.2 |
Description: Minimum order quantity: 1 unit of 1MG |
Staurosporine |
|||
00025 | Biotium | 100uG | EUR 166.8 |
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin, CF543 |
|||
00026 | Biotium | 500uG | EUR 592.8 |
Description: Minimum order quantity: 1 unit of 500uG |
Rhodamine phalloidin 300u |
|||
00027 | Biotium | 300 | EUR 414 |
Description: Minimum order quantity: 1 unit of 300 |
Biotin-xx-phalloidin |
|||
00028 | Biotium | 100U | EUR 513.6 |
Description: Minimum order quantity: 1 unit of 100U |
Fluorescein-phalloidin |
|||
00030 | Biotium | 300U | EUR 414 |
Description: Minimum order quantity: 1 unit of 300U |
Rhodamine 110 phalloidin |
|||
00032 | Biotium | 300ST | EUR 414 |
Description: Minimum order quantity: 1 unit of 300ST |
Sulforhodamine 101 (Texas-Red) Phalloidin |
|||
00033 | Biotium | 300EU | EUR 414 |
Description: Minimum order quantity: 1 unit of 300EU |
Phalloidin, CF405M |
|||
00034 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF405M |
|||
00034-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
CF488A-cAMP |
|||
00036 | Biotium | 100ug | EUR 206.4 |
Description: Minimum order quantity: 1 unit of 100ug |
CF640R-cAMP |
|||
00037 | Biotium | 100ug | EUR 206.4 |
Description: Minimum order quantity: 1 unit of 100ug |
Phalloidin, CF555 |
|||
00040 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF555 |
|||
00040-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF647 |
|||
00041 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF647 |
|||
00041-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF488A |
|||
00042 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF488A |
|||
00042-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF543 |
|||
00043 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF543 |
|||
00043-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF568 |
|||
00044 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF568 |
|||
00044-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF594 |
|||
00045 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF594 |
|||
00045-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF633 |
|||
00046 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF633 |
|||
00046-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF660R |
|||
00047 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF660R |
|||
00047-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF680R |
|||
00048 | Biotium | 300U | EUR 559.2 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF680R |
|||
00048-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF350 |
|||
00049 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF350 |
|||
00049-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF640R |
|||
00050 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF640R |
|||
00050-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF532 |
|||
00051 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF532 |
|||
00051-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF660C |
|||
00052 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF660C |
|||
00052-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF680 |
|||
00053 | Biotium | 300U | EUR 559.2 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF680 |
|||
00053-T | Biotium | 50U | EUR 176.4 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF430 |
|||
00054 | Biotium | 300U | EUR 538.8 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF430 |
|||
00054-T | Biotium | 50U | EUR 166.8 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF440 |
|||
00055 | Biotium | 300U | EUR 538.8 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF440 |
|||
00055-T | Biotium | 50U | EUR 166.8 |
Description: Minimum order quantity: 1 unit of 50U |
Cholera Toxin Subunit B, CF488A conjugate |
|||
00070 | Biotium | 100ug | EUR 313.2 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF568 conjugate |
|||
00071 | Biotium | 100ug | EUR 313.2 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF594 conjugate |
|||
00072 | Biotium | 100ug | EUR 313.2 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF640R conjugate |
|||
00073 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF532 conjugate |
|||
00074 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF543 conjugate |
|||
00075 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF620R conjugate |
|||
00076 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF633 conjugate |
|||
00077 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF660R conjugate |
|||
00078 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF680R conjugate |
|||
00079 | Biotium | 100ug | EUR 338.4 |
Description: Minimum order quantity: 1 unit of 100ug |
Human Transferrin, CF488A conjugate |
|||
00081 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF543 conjugate |
|||
00082 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF568 conjugate |
|||
00083 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF594 conjugate |
|||
00084 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF640R conjugate |
|||
00085 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF680R conjugate |
|||
00086 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF750 conjugate |
|||
00087 | Biotium | 1mg | EUR 186 |
Description: Minimum order quantity: 1 unit of 1mg |
HIV-1 tat recombinant antigen |
|||
00110-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 tat recombinant antigen |
|||
00110-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 GAG P24 Recombinant Antigen |
|||
00111-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV-1 GAG P24 Recombinant Antigen |
|||
00111-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV-1 nef recombinant antigen |
|||
00112-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 nef recombinant antigen |
|||
00112-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 env gp41 recombinant antigen |
|||
00113-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
HIV-1 env gp41 recombinant antigen |
|||
00113-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
HIV-2 GP 36 Recombinant Antigen |
|||
00114-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
HIV-2 GP 36 Recombinant Antigen |
|||
00114-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
HCV core recombinant antigen |
|||
00115-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
HCV core recombinant antigen |
|||
00115-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
HCV core recombinant antigen, Biotin conjugate |
|||
00115-V-B-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
HCV core recombinant antigen, Biotin conjugate |
|||
00115-V-B-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
HCV core recombinant antigen, FITC conjugate |
|||
00115-V-F-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
HCV core recombinant antigen, FITC conjugate |
|||
00115-V-F-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
HCV core recombinant antigen, Rhodamine |
|||
00115-V-R-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
HCV core recombinant antigen, Rhodamine |
|||
00115-V-R-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
HCV NS4 recombinant antigen NS4a+b |
|||
00116-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
HCV NS4 recombinant antigen NS4a+b |
|||
00116-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
00116-V-B-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
00116-V-B-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
00116-V-F-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
00116-V-F-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
00116-V-R-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
00116-V-R-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
HCV NS3 recombinant antigen |
|||
00117-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
HCV NS3 recombinant antigen |
|||
00117-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
HBV core recombinant antigen |
|||
00120-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
HBV core recombinant antigen |
|||
00120-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
HBV core recombinant antigen, Delta |
|||
00121-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
HBV core recombinant antigen, Delta |
|||
00121-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
HBV surface recombinant antigen HBsAg |
|||
00122-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
HBV surface recombinant antigen HBsAg |
|||
00122-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
HBV surface recombinant antigen HBsAg antigen |
|||
00123-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
HBV surface recombinant antigen HBsAg antigen |
|||
00123-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
HBV surface recombinant antigen HBsAg antigen |
|||
00124-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
HBV surface recombinant antigen HBsAg antigen |
|||
00124-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
HEV (Birma) ORF2 recombinant antigen |
|||
00131-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
HEV (Birma) ORF2 recombinant antigen |
|||
00131-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
HEV (Birma) ORF2 recombinant antigen |
|||
00132-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
HEV (Birma) ORF2 recombinant antigen |
|||
00132-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
00133-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
00133-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
T, Pallidum recombinant antigen p15 |
|||
00141-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: T. Pallidum recombinant antigen p15 (full length) |
T, Pallidum recombinant antigen p15 |
|||
00141-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: T. Pallidum recombinant antigen p15 (full length) |
T, Pallidum recombinant antigen p17 |
|||
00142-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: T. Pallidum recombinant antigen p17 (full length) |
T, Pallidum recombinant antigen p17 |
|||
00142-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: T. Pallidum recombinant antigen p17 (full length) |
T, Pallidum recombinant antigen p45 |
|||
00143-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: T. Pallidum recombinant antigen p45 (full length) |
T, Pallidum recombinant antigen p45 |
|||
00143-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: T. Pallidum recombinant antigen p45 (full length) |
T, pallidum recombinant antigen TmpA |
|||
00144-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: T. Pallidum recombinant antigen TmpA (full length) |
T, pallidum recombinant antigen TmpA |
|||
00144-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: T. Pallidum recombinant antigen TmpA (full length) |
HCV core 2-119aa recombinant antigen |
|||
00150-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
HCV core 2-119aa recombinant antigen |
|||
00150-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
HCV Core 24 Antigen |
|||
00151-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core 24 antigen. |
HCV Core 24 Antigen |
|||
00151-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core 24 antigen. |
HCV core recombinant antigen |
|||
00152-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core recombinant antigen a.a.105-302 |
HCV core recombinant antigen |
|||
00152-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core recombinant antigen a.a.105-302 |
HCV NS3 1192-1456 aa Recombinant Antigen |
|||
00153-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a |
HCV NS3 1192-1456 aa Recombinant Antigen |
|||
00153-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a |
HCV NS3 1359-1456aa antigen |
|||
00154-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
HCV NS3 1359-1456aa antigen |
|||
00154-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
HCV NS4 mosaic recombinant antigen |
|||
00155-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. |
HCV NS4 mosaic recombinant antigen |
|||
00155-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. |
HCV NS4 1916-1947aa recombinant antigen |
|||
00156-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS4 1916-1947aa recombinant antigen. |
HCV NS4 1916-1947aa recombinant antigen |
|||
00156-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS4 1916-1947aa recombinant antigen. |
HCV NS5 2061-2302aa recombinant antigen |
|||
00157-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS5 2061-2302aa recombinant antigen. |
HCV NS5 2061-2302aa recombinant antigen |
|||
00157-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS5 2061-2302aa recombinant antigen. |
HCV NS5 2212-2313aa recombinant antigen |
|||
00158-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS5 2212-2313aa recombinant antigen. Available genotypes: 1a, 1b, 2a, 2b, 3a, 3b, 4, 5, 6a. |
HCV NS5 2212-2313aa recombinant antigen |
|||
00158-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS5 2212-2313aa recombinant antigen. Available genotypes: 1a, 1b, 2a, 2b, 3a, 3b, 4, 5, 6a. |
HAV VP1-P2A recombinant antigen |
|||
00159-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HAV VP1-P2A recombinant antigen a.a. 722-830. |
HAV VP1-P2A recombinant antigen |
|||
00159-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HAV VP1-P2A recombinant antigen a.a. 722-830. |
HAV VP4-VP2 recombinant antigen |
|||
00160-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HAV VP4-VP2 recombinant antigen a.a. 55-164. |
HAV VP4-VP2 recombinant antigen |
|||
00160-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HAV VP4-VP2 recombinant antigen a.a. 55-164. |
HAV P2C-P3A recombinant antigen |
|||
00161-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HAV P2C-P3A recombinant antigen a.a. 1492-1606. |
HAV P2C-P3A recombinant antigen |
|||
00161-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HAV P2C-P3A recombinant antigen a.a. 1492-1606. |
HAV P3C recombinant antigen |
|||
00162-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HAV P3C recombinant antigen a.a. 1643-1743. |
HAV P3C recombinant antigen |
|||
00162-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HAV P3C recombinant antigen a.a. 1643-1743. |
HAV VP3 recombinant antigen |
|||
00163-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HAV VP3 recombinant antigen a.a. 304-415. |
HAV VP3 recombinant antigen |
|||
00163-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HAV VP3 recombinant antigen a.a. 304-415. |
HAV VP1-P2A recombinant antigen |
|||
00164-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HAV VP1-P2A recombinant antigen a.a. 669-782. |
HAV VP1-P2A recombinant antigen |
|||
00164-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HAV VP1-P2A recombinant antigen a.a. 669-782. |
HAV HAV P2C recombinant antigen |
|||
00165-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HAV HAV P2C recombinant antigen a.a. 1121-1234. |
HAV HAV P2C recombinant antigen |
|||
00165-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HAV HAV P2C recombinant antigen a.a. 1121-1234. |
HAV P2C-P3A recombinant antigen |
|||
00166-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HAV P2C-P3A recombinant antigen a.a. 1392-1521. |
HAV P2C-P3A recombinant antigen |
|||
00166-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HAV P2C-P3A recombinant antigen a.a. 1392-1521. |
HIV-1 p17/24/gp120-gp41 recombinant antigen, |
|||
00168-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV-1 p17/24/gp120-gp41 recombinant antigen, |
|||
00168-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV-1 p17/24/gp120 antigen |
|||
00169-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
HIV-1 p17/24/gp120 antigen |
|||
00169-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
HIV-1 gp41 recombinant antigen, |
|||
00170-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 gp41 recombinant antigen. |
HIV-1 gp41 recombinant antigen, |
|||
00170-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 gp41 recombinant antigen. |
HIV-1 gp41 Long recombinant antigen, |
|||
00171-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 gp41 Long recombinant antigen. |
HIV-1 gp41 Long recombinant antigen, |
|||
00171-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 gp41 Long recombinant antigen. |
HIV-2 gp32 recombinant antigen |
|||
00173-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-2 gp32 recombinant antigen. . |
HIV-2 gp32 recombinant antigen |
|||
00173-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-2 gp32 recombinant antigen. . |
HIV-1 p24 recombinant antigen, |
|||
00174-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 p24 recombinant antigen. |
HIV-1 p24 recombinant antigen, |
|||
00174-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 p24 recombinant antigen. |
HIV 1, 2 envelope recombinant antigen |
|||
00175-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
HIV 1, 2 envelope recombinant antigen |
|||
00175-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
HIV 1 envelope recombinant antigen |
|||
00176-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. |
HIV 1 envelope recombinant antigen |
|||
00176-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. |
HIV 1 p24 core recombinant antigen |
|||
00177-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV 1 p24 core recombinant antigen. |
HIV 1 p24 core recombinant antigen |
|||
00177-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV 1 p24 core recombinant antigen. |
HIV type O envelope antigen |
|||
00178-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. |
HIV type O envelope antigen |
|||
00178-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. |
HIV -2 env gp36 recombinant antigen |
|||
00179-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702. |
HIV -2 env gp36 recombinant antigen |
|||
00179-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702. |
HIV 2 gp36 envelope antigen |
|||
00180-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
HIV 2 gp36 envelope antigen |
|||
00180-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
Advances in medical treatment of various pathophysiological conditions require the development of better therapeutic agents, as well as combinations of therapeutic agents required by the integrated device biomaterials that can serve as sensors and operator. The combination of micro systems and nano-fabrication with intelligent biomaterials that have the ability to feel and response is a promising avenue for the development of better medical system diagnostic and therapeutic.